Dr. Reddy's Laboratories enters into a distribution agreement with AstraZeneca Pharma

01 Jun 2015 Evaluate

Dr. Reddy's Laboratories has entered into a distribution agreement with AstraZeneca Pharma India (AZPIL) for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed dose combination with metformin respectively, promoted and distributed in the Indian market.

Dr. Reddy’s Laboratories will be distributing Riax and Riax M in India. This partnership strengthens Dr. Reddy’s diabetes franchise in India. It enables AstraZeneca to expand usage of this molecule through wider reach to physicians and benefiting more number of diabetic patients.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1198.10 -26.20 (-2.14%)
29-Jan-2026 13:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1596.45
Dr. Reddys Lab 1198.10
Cipla 1318.00
Zydus Lifesciences 886.30
Lupin 2120.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×